Heparin

Generic Name: Heparin

Brand Names: Heparin Leo

Drug Type: Small Molecule

Chemical Formula: -

CAS Number: 9005-49-6

Unique Ingredient Identifier: T2410KM04A

Background: Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (fac...

Indication: Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin ther...

Associated Conditions: Blunt Injury, Clotting, Coagulopathy, Consumption, Contusions, Deep vein thrombosis postoperative, Disseminated Intravascular Coagulation (DIC), External Hemorrhoid, Inflammation, Inflammatory, non-infectious pruritic dermatosis, Interstitial Cystitis, Post procedural pulmonary embolism, Pulmonary Embolism, ST Segment Elevation Myocardial Infarction (STEMI), Sprains, Thromboembolism, Unstable Angina Pectoris, Venous Thrombosis (Disorder), Hematomas, Peripheral arterial embolism, Thromboembolic phenomena, Varicosities of the great saphenous vein

Associated Therapies: Circulation, Extracorporeal, Dialysis therapy, Transfusions, Maintenance of patency of IV injection devices

Clinical Trials

Reduced Anticoagulation Targets in ECLS (RATE)

Phase 3

Conditions: Heart Failure
Extracorporeal Membrane Oxygenation
Respiratory Failure
Bleeding
Thrombosis

Interventions: Drug: LMWH
Drug: Heparin

First Posted Date: 2020-09-02

Last Posted Date: 2021-10-15

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 330

Registration Number: NCT04536272

Locations: 🇳🇱
OLVG, location East, Amsterdam, Noord-Holland, Netherlands
🇳🇱
Amsterdam UMC, location AMC, Amsterdam, Noord-Holland, Netherlands
🇳🇱
Radboud UMC, Nijmegen, Gelderland, Netherlands

and more 6 locations

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

Phase 3

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Interventions: Drug: Bivalirudin 250 MG Injection
Drug: Heparin

First Posted Date: 2020-08-31

Last Posted Date: 2020-08-31

Lead Sponsor: Changhai Hospital

Target Recruit Count: 236

Registration Number: NCT04532333

Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19

Phase 4

Conditions: Covid19
Pneumonia

Interventions: Drug: Enoxaparin
Drug: Heparin sodium

First Posted Date: 2020-08-28

Last Posted Date: 2020-08-31

Lead Sponsor: Clinica San Camilo, Argentina

Target Recruit Count: 200

Registration Number: NCT04530578

Locations: 🇦🇷
Clinica San Camilo, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina

Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection

Phase 3

Conditions: Covid19
SARS-CoV Infection
Coagulopathy
Pneumonia, Viral

Interventions: Drug: Enoxaparin
Drug: Methylprednisolone
Drug: unfractionated heparin

First Posted Date: 2020-08-27

Last Posted Date: 2021-05-06

Lead Sponsor: Massimo Girardis

Target Recruit Count: 210

Registration Number: NCT04528888

Locations: 🇮🇹
ICU- University Hospital Modena, Modena, Italy

CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19

Not Applicable

Completed

Conditions: Acute Kidney Injury
Covid19

Interventions: Drug: unfractionated Heparin

First Posted Date: 2020-07-27

Last Posted Date: 2022-06-08

Lead Sponsor: University of Sao Paulo General Hospital

Target Recruit Count: 118

Registration Number: NCT04487990

Locations: 🇧🇷
University of São Paulo General Hospital, São Paulo, SP, Brazil

Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia

Phase 3

Withdrawn

Conditions: COVID-19

Interventions: Drug: Methylprednisolone
Drug: Heparin

First Posted Date: 2020-07-24

Last Posted Date: 2021-08-11

Lead Sponsor: D'Or Institute for Research and Education

Registration Number: NCT04485429

Locations: 🇧🇷
D'Or Institute for Research and Education, Rio de Janeiro, Brazil

Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMI

Not Applicable

Conditions: STEMI With Multivessel Coronary Disease

Interventions: Drug: Heparin
Drug: Bivalirudin

First Posted Date: 2020-07-17

Last Posted Date: 2022-05-02

Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University

Target Recruit Count: 100

Registration Number: NCT04475835

Locations: 🇨🇳
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Phase 4

Terminated

Conditions: COVID-19

Interventions: Drug: Enoxaparin sodium
Drug: Unfractionated heparin
Drug: Fondapariniux
Drug: Argatroban

First Posted Date: 2020-05-28

Last Posted Date: 2023-09-21

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 14

Registration Number: NCT04406389

Locations: 🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States